1
Total investments
1
Early stage
0
Mid stage
0
Late stage
10y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Jan 2016
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Experience · 6 entries
All (6)
Investments (1)
Founder (1)
Board (1)
2016
Board Member
Jan 2016
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
2015
L
Longitude Capital Management
Venture Partner
Nov 2015
2007
C
C.T. Services Americas, Inc.
Managing Director
Jul 2007
D
DA Advisors, LLC
Managing Director
Jan 2007
2006
C
Celtic Pharma Management, L.P.
Managing Director
Apr 2006
Show all 6 entries ↓